IRMD Earnings Prediction
The chart below shows how IRMD performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IRMD sees a -4.83% change in stock price 10 days leading up to the earnings, and a -2.45% change 10 days following the report. On the earnings day itself, the stock moves by +2.87%. This data can give you a slight idea of what to expect for the next quarter's release.
IRMD Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
19.39M
11.10%
5.80%
Gross Margin
76.13%
-0.95%
-1.69%
Operating Margin
29.91%
1.15%
-5.32%
Net Margin
26.54%
2.04%
-3.67%
EPS
0.40
11.11%
0.00%
No Data Available
IRMD Earnings Analysis
IRadimed Corp Corporation (IRMD.O) Earnings Conference Call
Positive
Record Revenue Achievement: Record revenue of over $19.4 million for Q4 2024, marking the 14th consecutive record quarter.
Earnings Growth Increase: GAAP diluted earnings per share increased by 11% from Q4 2023, demonstrating strong earnings growth.
Domestic Sales Surge: Domestic sales increased by 21% to $16.5 million, indicating robust demand in the domestic market.
Device Revenue Increase: Device revenue increased by 12% to $14.3 million in Q4 2024, driven by strong pump sales.
Q4 Operating Income Performance: Operating income for Q4 was $5.8 million, maintaining a solid operating margin of 30%.
Adjusted Net Income Growth: Adjusted net income on a non-GAAP basis was $0.44 per diluted share for Q4 2024, up from $0.39 in Q4 2023, reflecting a 12% year-over-year increase.
Cash Flow Improvement: Cash from operations increased to $6 million for Q4 2024, up from $3.9 million in the same period last year, showcasing improved efficiency in working capital management.
Facility Construction Progress: The new facility is under construction and on track for completion by June 2025, which is expected to support future growth.
Negative
Earnings Miss Reported: IRadimed Corporation missed earnings expectations with reported EPS of $0.44, falling short of the expected $0.45.
International Sales Decline: International sales decreased by 24% to $2.9 million, indicating a significant decline in global market performance.
Gross Margin Decline: The gross margin for Q4 2024 was slightly lower at 76.1% compared to 76.9% in Q4 2023, suggesting a decrease in profitability.
Rising Operating Expenses: Operating expenses increased to $9 million or 46% of revenue, up from $8.3 million or 47% of revenue in Q4 2023, indicating rising costs.
Free Cash Flow Decline: Free cash flow declined to $2.9 million from $3.3 million in the same period last year, reflecting challenges in cash generation despite operational improvements.
IRMD FAQs
How does IRMD typically perform around its earnings report dates?
Is IRadimed Corp (IRMD) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
IRMD Earning Call Sentiment
IRadimed Corporation (NASDAQ:IRMD) Q4 2024 Earnings Call Transcript
IRMD.O
0.65%Positive
The earnings call presents mixed signals. Financial performance shows growth in revenue and net income, but the EPS miss and international sales decline are concerning. The FDA clearance delay and increased operating expenses add to uncertainties. However, raised full-year guidance and strong demand for monitors are positive indicators. The lack of a share repurchase program and unclear management responses in the Q&A section further contribute to a neutral sentiment. Without market cap data, it's challenging to predict a stronger reaction.
